[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,42,64,90,120,143,169,194,223,246,268,287,307,326,345,365,394,433,451,460,471,514,539,562,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053771","clinical-study-to-evaluate-the-impact-of-the-accu-chek-smartguide-cgm-solution-on-the-mean-change-in-time-in-range-compared-with-self-monitoring-of-blood-glucose-in-participants-with-type-1-and-type-2-diabetes-mellitus-100053771",false,"NCT06704672","Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus","Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range of 70 - 180 mg\u002Fdl Compared to SMBG","Inclusion Criteria:\n\n* Type 1 Diabetes mellitus (T1D) or Type 2 Diabetes mellitus (T2D) diagnosed at least 12 months prior to screening, using multiple daily injection (MDI) regime for at least six months prior to screening\n* Performing SMBG, no CGM\u002Fflash glucose monitoring (FGM) use during the last six months prior screening\n* HbA1c ≥8% and ≤10% based on analysis from a local laboratory\n\nExclusion Criteria:\n\n* Untreated adrenal or thyroid insufficiency\n* Severe visual impairment\n* Significant renal impairment: eGFR \\\u003C30 ml\u002Fmin within last one year\n* Serious acute or chronic concomitant disease or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject\n* Hematocrit greater than 10% below the lower limit of normal\n* Pregnancy (lack of negative pregnancy test - except in case of menopause, sterilization or hysterectomy - self-reported), planned pregnancy, or breast feeding\n* Allergic to the adhesive (glue or tape)\n* Skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) at the sensor application sites\n* Sickle cell disease, or hemoglobinopathy\n* Elective surgery planned that requires general anesthesia during study participation\n* Current or anticipated acute uses of glucocorticoids (oral, injectable, or intravenous)\n* Medical conditions that, per investigator determination, make it inappropriate or unsafe to target an HbA1c of \\\u003C7%. Conditions may include but are not limited to: heart failure, unstable cardiovascular disease, recent myocardial infarction, ventricular rhythm disturbances, recent transient ischemic attack or cerebrovascular accident, significant malignancy\n* Chronic use of opiates, opioids, morphinomimetics more than three times per week, which has not stopped at least 30 days prior to screening and any other medication interfering with the assessment of pain, as per investigator's discretion\n* Intake of hydroxyurea (hydroxycarbamide), levodopa, methyldopa, ascorbic acid, acetylsalicylic acid (≥300mg), which has not stopped at least 30 days prior to screening\n* Magnetic resonance tomography (MRT), computed tomography (CT), X-ray, radiofrequency ablation, high-frequency electrical heat or high intensity focused ultrasound planned during the course of the study\n* Planned flight or high-altitude hike (\\>3000 m) during baseline and assessment periods\n* Shift-worker (night-shifts)\n* On or planning to start a diet intended for weight change\n* Currently abusing illicit and\u002For prescription drugs or alcohol as judged by the investigator\n* Any other physical or psychological disease or psychiatric disorder that could limit adherence to the required study tasks and interfere with the normal conduct of the study as judged by the investigator\n* Dependency (e.g., employee, co-worker or family member) on sponsor, investigator or companies active in the field of CGM (e.g. Dexcom, Abbott, Menarini, Medtronic) or their subsidiaries\n* Participation in another clinical study at the same time","ALL","18 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.\n\nThe goal of the study is to investigate the impact of the Accu-Chek SmartGuide CGM solution on the change in overall time in range (TIR) of blood glucose concentrations of 70-180 mg\u002Fdl compared with that using self-monitoring of blood glucose (SMBG).",[27,28],"Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2025-04-14",{"date":37,"type":21},"2027-05-30",{"name":39,"class":40},"Hoffmann-La Roche","INDUSTRY",18,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100053900","gateway-safety-evaluation-of-the-minimed-nmx8-aid-system-in-children-and-adults-living-with-diabetes-100053900","NCT07228117","GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes","Inclusion Criteria:\n\n1. Age at time of screening according to diabetes type:\n\n   1. T1D: Age 7-85 years\n   2. T2D: Age 18-85 years\n2. Has a clinical diagnosis of diabetes for a minimum per diabetes type below:\n\n   1. T1D (Age 7-85 years): Diagnosis of T1D for at least 6 months, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.\n   2. T2D (Age 18-85 years): Diagnosis of insulin-requiring T2D for 1 year or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis\n3. Is willing to provide informed consent\u002Fassent for participation.\n4. Subject or parent\u002Fcaregiver is literate and able to read the language (English or Spanish) offered in the study pump or study pump materials.\n5. Is willing to wear the system continuously throughout the study.\n6. Has results of a retinal eye examination on record prior to enrollment, per guidelines by the American Diabetes Association according to age, duration of diabetes and type of diabetes:\n\n   1. T1D adults (Age 18-85 years):\n\n      I. Initial retinal eye exam within 5 years of diagnosis. II. If the duration of type 1 diabetes is longer than 5 years, a retinal examination should have been performed within the last 12-18 months.\n   2. T2D adults (Age 18-85 years):\n\n      I. Results of a retinal eye exam, performed within the last 12-18 months, should be on record.\n   3. T1D pediatric (Age 7-17 years):\n\n   I. No exam is required if under the age of 10 years unless the duration of diabetes is more than 3 years.\n\n   II. For children over the age of 10, a retinal exam should have been performed within 24 months of enrollment in the study.\n\n   Per the investigator's discretion: If a potential participant is deemed to be at high risk, a retinal eye exam, performed within the last 12 months prior to screening, should be on record.\n7. Is willing to upload study pump data via an app or computer.\n8. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:\n\n   1. Humalog™\\* (insulin lispro injection)\n   2. NovoLog™\\* (insulin aspart solution for injection) or an interchangeable biosimilar (for example, Kirsty™\\*)\n   3. NovoRapid™\\* (insulin aspart solution for injection)\n   4. Admelog™\\* (insulin lispro injection)\n   5. Merilog™\\* (insulin aspart)\n   6. Fiasp™\\* (ultra-rapid-acting insulin aspart)\n   7. Lyumjev™\\* (ultra-rapid-acting insulin lispro)\n   8. Authorized generic insulin aspart\n   9. Authorized generic insulin lispro\n\nExclusion Criteria:\n\n1. Unable to consent due to a mental or intellectual disability.\n2. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following, during the 6 months prior to screening:\n\n   1. Medical assistance (i.e., Paramedics, Emergency Room \\[ER\\] or Hospitalization)\n   2. Coma or\n   3. Seizures\n3. Has a history of 1 or more episodes of diabetic ketoacidosis (DKA) in the last 6 months prior to screening visit.\n4. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.\n5. Has any unresolved adverse skin condition in the area of sensor or infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).\n6. Currently pregnant or planning to become pregnant during the time period of study participation\n\n   1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening\n   2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable\n7. At investigator discretion, has hypothyroidism or hyperthyroidism that is not adequately treated.\n8. Has diagnosis of adrenal insufficiency.\n9. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit.\n10. T1D: Is using non-insulin anti-hyperglycemic medication, other than metformin and\u002For Glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) containing medications (e.g., Mounjaro), in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin and\u002For GLP-1\u002FGIP have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin and\u002For GLP-1\u002FGIP must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study.\n11. T2D: Is using non-insulin anti-hyperglycemic medication, other than metformin, GLP-1 \u002FGIP containing medications (e.g., Mounjaro), or Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, in the 8 weeks prior to screening.\n\n    1. Participants who have stopped using metformin, GLP-1\u002FGIP or SGLT2 have done so at least 8 weeks prior to screening.\n    2. Participants currently taking metformin, GLP-1\u002FGIP or SGLT2 must be on a steady dose and remain on the same dose during study participation. Dose changes and reasons for changes will be documented throughout the study\n12. Is using sulfonylureas and meglitinides, e.g., repaglinide, in the 8 weeks prior to screening.\n13. Is using inhalable insulin in the 8 weeks prior to screening.\n14. Is using hydroxyurea at time of screening or plans to use it during the study\n15. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study.\n16. Is, at the discretion of the investigator, abusing drugs or alcohol.\n17. Is, in the opinion of the investigator, not able to perform all study procedures safely.\n18. Has a history of visual impairment which would not allow subject, even with the help of a caregiver, to participate in the study and perform all study procedures safely, as determined by the investigator.\n19. Has elective surgery planned that requires general anesthesia during the course of the study.\n20. Has sickle cell disease or other hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.\n21. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.\n22. Is diagnosed with current eating disorder such as anorexia or bulimia.\n23. Blood disorder or dyscrasia within 3 months prior to screening, which in the investigator's opinion could interfere with determination of HbA1c\n24. Is on dialysis.\n25. Has an estimated Glomerular Filtration Rate (eGFR) \\\u003C30.\n26. Has celiac disease that is not adequately treated as determined by the investigator.\n27. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n28. Has had any of the following cardiovascular events more than 1 year prior to screening and should not participate at the discretion of the investigator: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.\n29. Is a member of the research staff involved with the study.\n30. Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and\u002For adult siblings).","7 Years","85 Years",{"count":51,"type":21},400,[24],"The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5\u002FSimplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5\u002FSimplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.",[27,28],"2026-07-09",{"date":32,"type":33},{"date":58,"type":33},"2026-02-02",{"date":60,"type":21},"2027-01",{"name":62,"class":40},"Medtronic MiniMed, Inc.",38,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100633512","phase-2-study-to-evaluate-hm15275-in-subjects-with-type-2-diabetes-mellitus-100633512","NCT07527650","Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus","A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus","Key Inclusion Criteria\n\n1. Participant's age at the time of signing the informed consent:\n\n   * United States: 18 to 75 years (inclusive)\n2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening\n3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg\u002Fday) for at least 3 months prior to screening\n4. BMI ≥25 kg\u002Fm² and ≤50 kg\u002Fm²\n5. Body weight change \\\u003C5% over the past 3 months prior to screening\n6. Capable of giving signed informed consent and willing to comply with all protocol procedures\n\nKey Exclusion Criteria\n\n1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening\n2. Poor glycemic control (fasting plasma glucose \\>270 mg\u002FdL)\n3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months\n4. Clinically significant cardiovascular disease (e.g., NYHA class III\u002FIV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months)\n5. History of pancreatitis or factors increasing the risk of pancreatitis\n6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2\n7. Clinically significant liver disease, renal impairment (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²), or abnormal laboratory findings at screening\n8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening","75 Years",{"count":73,"type":21},180,[75],"PHASE2","This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.",[28,78],"T2DM",[28,78],"2026-06-30",{"date":82,"type":33},"2026-07-02",{"date":84,"type":33},"2026-05-18",{"date":86,"type":21},"2027-10",{"name":88,"class":40},"Hanmi Pharmaceutical Company Limited",10,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":98,"maxAge":71,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100637152","efficacy-of-the-omnipod-6-system-compared-with-the-omnipod-5-system-100637152","NCT07579702","Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System","Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes and Suboptimal Glycemia","STRIVE 2","Inclusion Criteria:\n\n* Age at time of consent 14-75 years (inclusive)\n* Type 1 diabetes diagnosis for at least 6 months or type 2 diabetes diagnosis for at least 1 year, based on Investigator's clinical judgment\n* Basal\u002FBolus insulin delivery via multiple daily doses or insulin pump with or without automation\n* HbA1c ≥ 7.5%\n* Average # of user-initiated boluses less than 4 per day over the 14 days prior to screening through review of device data or self-reported if non-pump user\n* Average # of user-initiated boluses less than 4 per day over 14 days, during Standard Therapy Phase through review of device data or self-reported if non-pump user\n* Currently using a continuous glucose monitor\n* Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents.\n* Participant agrees to provide their own insulin for the duration of the study\n* Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and\u002For caregiver can safely operate all study devices and can adhere to the protocol\n* Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and\u002For caregiver can safely operate all study devices and can adhere to the protocol\n* If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor (T2D only), or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.\n* Willing to wear the system continuously throughout the study\n* Willing and able to sign the Informed Consent Form (ICF) or has a parent\u002Fguardian willing and able to sign the ICF. Assent will be obtained from adolescent participants aged \\\u003C 18 years per local regulatory requirements\n* Able to read and understand English and operate the study device in English\n* If of childbearing potential, willing and able to have pregnancy testing\n\nExclusion Criteria:\n\n* Any medical condition, which in the opinion of the investigator, would put the participant at an unacceptable safety risk\n* Current or known history of coronary artery disease that is not stable with medical management per investigator judgment, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening\n* Any planned surgery during the study which could be considered major in the judgment of the investigator\n* History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered mental and\u002For physical status, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.\n* History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness or infusion failure\n* Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement\n* Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c\n* Use of hydroxyurea\n* Plans to receive blood transfusion over the course of the study\n* Has taken systemic steroids (oral or injectable) within 4 weeks or has had a local steroid injection (e.g. intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study\n* Has type 1 diabetes and is taking non insulin glucose lowering medication other than metformin and GLP1, in the 4 weeks prior to screening.\n* Has type 2 diabetes and is taking sulfonylureas in the 4 weeks prior to screening\n* Pregnant or lactating, or of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner).\n* Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period\n* Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment\n* Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned","14 Years",{"count":100,"type":21},200,[24],"This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.",[28,27],[105,106,107,108,109,110,111],"Omnipod","Automated Insulin Delivery","T2D","T1D","Type 2 Diabetes","Type 1 Diabetes","AID",{"date":82,"type":33},{"date":114,"type":33},"2026-05-13",{"date":116,"type":21},"2027-02-01",{"name":118,"class":40},"Insulet Corporation",12,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100633037","evaluation-of-the-fully-closed-loop-omnipod-system-in-type-2-diabetes-100633037","NCT07521475","Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes","EVOLVE: Evaluation of the Fully Closed Loop Omnipod® System for Safety and Efficacy in Adults With Type 2 Diabetes","EVOLVE","Inclusion Criteria:\n\n1. Age at time of consent 18-75 years (inclusive)\n2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening\n3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection.\n\n   * Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin).\n   * Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump\n   * Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group\n4. For basal only users, screening A1C ≥7.5% and \\\u003C14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \\\u003C14.0%.\n\n   • A1C measurement within 28 days prior to enrollment is acceptable\n5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic\u002Fbiosimilar equivalents\n6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor\n7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities\n8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase)\n9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety).\n10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol\n11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase\n12. Willing and able to sign the Informed Consent Form (ICF)\n13. Able to read and understand English\n14. If of childbearing potential, willing and able to have pregnancy testing\n\nExclusion Criteria:\n\n1. Use of an automated insulin delivery pump within 3 months prior to screening\n2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse.\n3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening\n4. Any planned surgery during the study which could be considered major in the opinion of the Investigator\n5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.\n6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis\n7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement\n8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c\n9. Plans to receive blood transfusion over the course of the 26-week trial phase.\n10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).\n11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase.\n12. Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase\n13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment\n14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned",{"count":129,"type":21},350,[24],"A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal\u002Fbolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks",[28],[106,107,109,105,111,134,135],"Fully closed loop","FCL",{"date":82,"type":33},{"date":138,"type":33},"2026-04-30",{"date":140,"type":21},"2027-09-23",{"name":118,"class":40},19,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100635575","an-observational-study-called-finexplorer-to-learn-more-about-how-well-finerenone-works-in-adults-in-spain-with-chronic-kidney-disease-ckd-linked-to-type-2-diabetes-by-looking-at-changes-in-a-ckd-risk-score-100635575","NCT07554469","An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score","An Observational Prospective Study to Analyse Changes in the Klinrisk Chronic Kidney Disease Progression Model Score in a Cohort of Patients With CKD Associated With Type 2 Diabetes Treated With Finerenone in Spain","FINEXPLORER","Inclusion Criteria:\n\n* Patients who sign the written informed consent to participate in the study.\n* Men or women aged ≥18 years.\n* Patients with CKD associated with type 2 diabetes and albuminuria (UACR \\>30 mg\u002Fg).\n* Patients initiated on finerenone in routine clinical practice, according to the Summary of Product Characteristics (SmPC), within the 2 months prior to inclusion.\n\nExclusion Criteria:\n\n* eGFR \\\u003C 25 mL\u002Fmin\u002F1.73 m².\n* Severe hepatic impairment.\n* Clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms.\n* Confirmed significant non-diabetic renal disease, including clinically relevant renal artery stenosis.\n* Uncontrolled arterial hypertension (mean sitting systolic blood pressure \\[SBP\\] ≥160 mmHg or diastolic blood pressure \\[DBP\\] ≥100 mmHg at inclusion).\n* Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or a potassium-sparing diuretic that has not been discontinued at least 4 weeks prior to inclusion.",{"count":152,"type":21},500,"OBSERVATIONAL","This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.\n\nChronic kidney disease (CKD) is common in people with type 2 diabetes. It can get worse over time and may lead to kidney failure and heart problems. Doctors often track kidney health using blood and urine tests, including the estimated glomerular filtration rate (eGFR) and the urine albumin-to-creatinine ratio (UACR). There are also tools that combine routine laboratory test results to estimate a person's risk of their kidney disease getting worse. One of these tools is called the Klinrisk model.\n\nThe study drug, finerenone, is already approved for doctors to prescribe to patients with CKD associated with T2D and albumin in the urine.\n\nFinerenone works by blocking the mineralocorticoid receptor, a protein involved in inflammation and scarring in the kidneys and heart. The study drug, finerenone, is a non-steroidal mineralocorticoid receptor modulator that aims to reduce harmful kidney and heart changes.\n\nThe main purpose of this study is to determine whether the Klinrisk score improves after 2 years of treatment with finerenone in adults with CKD associated with T2D who are treated in routine care. To achieve this, researchers will collect data on:\n\n* Clinical characteristics of participants, including their medical history related to CKD and T2D.\n* Variables used to assess the CKD progression, such as eGFR, UACR, and Blood Urea Nitrogen (BUN).\n* Participants' glucose, hemoglobin and potassium levels.\n\nThe study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.\n\nData will be collected from April 2026 to April 2029 and will cover a period of up to 24 months per participant. Data collection will occur over 5 visits that coincide with routine clinical care: inclusion, follow-up visits at 6, 12, and 18 months (±1 month), and a final visit at 24 months (±1 month).",[156,28],"Chronic Kidney Disease",[158,156,28],"Finerenone","2026-06-26",{"date":161,"type":33},"2026-06-29",{"date":163,"type":33},"2026-05-26",{"date":165,"type":21},"2029-04-30",{"name":167,"class":40},"Bayer",1,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100645220","llm-assisted-diabetes-and-hypertension-management-by-village-doctors-100645220","NCT07678658","LLM-Assisted Diabetes and Hypertension Management by Village Doctors","Large Language Model-Assisted Decision Support for Improving Village Doctors' Integrated Management of Patients With Type 2 Diabetes and Hypertension: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Certified village doctors or primary care physicians practicing in rural primary healthcare institutions;\n2. At least 1 year of experience in the management of chronic diseases, including type 2 diabetes mellitus and hypertension;\n3. Able to complete the case assessment tasks required by the study;\n4. Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\nNone.",true,"80 Years",{"count":179,"type":21},20,[24],"This is a prospective, assessor-blinded, randomized controlled study designed to evaluate whether large language model (LLM)-assisted decision support can improve village doctors' abilities in the comprehensive management of patients with type 2 diabetes mellitus and hypertension.\n\nFor each standardized clinical case, two village doctors will independently review the same patient information and develop management plans. An independent statistician will randomly assign one doctor to receive LLM-assisted decision support, while the other will complete the assessment without assistance. All management plans and questionnaire responses will be de-identified and evaluated by an independent expert panel blinded to group allocation. The study will compare the quality of clinical decision-making, risk assessment, treatment recommendations, and follow-up planning between the LLM-assisted and control groups.",[28,183],"Hypertension","NOT_YET_RECRUITING","2026-06-25",{"date":187,"type":33},"2026-07-01",{"date":187,"type":21},{"date":190,"type":21},"2026-07-14",{"name":192,"class":193},"Jiangsu Taizhou People's Hospital","OTHER",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":221,"locationsCount":168},"100612610","phase-4-dual-vs-triple-lipid-lowering-therapy-in-type-2-diabetes-mellitus-patients-with-elevated-ldl-cholesterol-100612610","NCT07255820","Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","Comparative Efficacy and Safety of Dual Versus Triple Lipid-Lowering Therapies (Rosuvastatin\u002FEzetimibe, Bempedoic Acid\u002FEzetimibe, and Rosuvastatin\u002FEzetimibe\u002FBempedoic Acid ) in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","Inclusion Criteria:\n\n* Males and females\n* Age 35-60 years\n* HbA1c ≥ 7.0 (≥ 48 mmol\u002Fmol)\n* On stable anti-diabetic therapy for at least 3 months\n* LDL-C \\> 100 mg\u002FdL on at least two occasions\n* Diagnosed with hypercholesterolemia\n* Establish high cardiovascular risk (e.g, previous MI, stroke or atherosclerosis) or\n* ≥2 cardiovascular risk factors (hypertension, smoking, obesity, family history)\n* BMI \\>23 - \\\u003C32(WHO Asian Criteria)\n* No prior statin side effects\n\nExclusion Criteria:\n\n* HbA1c \\>10 % (86 mmol\u002Fmol)\n* BMI \\> 32\n* Type 1 Diabetes, gestational diabetes\n* Pregnancy or lactation\n* Acute liver disease or ALT\u002FAST levels \\> 3× the upper limit of normal\n* Renal failure (GFR \\\u003C 30 mL\u002Fmin)\n* Uncontrolled hypothyroidism or nephrotic syndrome\n* Recent cancer diagnosis (last 6 months)\n* Current use of other lipid-lowering agents (e.g., fibrates or PCSK9 inhibitors)\n* Known allergy to any component\n* Statin intolerance with severe adverse effects (e.g., rhabdomyolysis)","35 Years","60 Years",{"count":204,"type":21},126,[206],"PHASE4","This Open-label, randomized clinical trial evaluates the comparative efficacy and safety of dual versus triple lipid-lowering therapy using rosuvastatin, ezetimibe, and bempedoic acid in patients with type 2 diabetes mellitus and elevated LDL cholesterol. The study aims to determine whether adding bempedoic acid to standard dual therapy provides superior lipid control without compromising safety. The 126 participants, aged 35 - 60 years will be randomly assigned to one of three treatment groups for 12 weeks, and their lipid profiles, glycemic control, and adverse effects will be monitored.The total duration of study will be 6 months, with a 3 months individual treatment period.",[28,209],"Hypercholesterolemia \u002F Elevated LDL Cholesterol",[211,212,213,214,215,109],"Lipid-lowering therapy,","Rosuvastatin, Ezetimibe, Bempedoic Acid","Dual therapy vs Triple therapy","LDL-C","Dyslipidemia","2026-06-23",{"date":159,"type":33},{"date":219,"type":33},"2026-01-01",{"date":80,"type":21},{"name":222,"class":193},"Bahria University",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},"100619933","phase-3-a-clinical-study-to-evaluate-the-effects-of-enicepatide-ro7795068-in-participants-with-obesity-or-overweight-and-type-2-diabetes-100619933","NCT07351058","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes","Enith2","Inclusion Criteria:\n\n* Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n* Diagnosis of type 2 diabetes mellitus (T2DM) according to WHO classification or other locally applicable standards with HbA1c ≥6.5% to ≤10% determined by laboratory test at screening, and on stable oral therapy for at least 3 months prior to screening (if applicable). T2DM may be treated with diet\u002Fexercise alone or any oral anti-hyperglycemic medication (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1 RA-based therapy.\n* Body mass index (BMI) ≥27.0 kg\u002Fm\\^2\n* History of ≥1 self-reported unsuccessful diet\u002Fexercise effort to lose body weight\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus (T1DM) or any lifetime history of ketoacidosis or history of hyperosmolar state\u002Fcoma within 12 months prior to screening\n* Have had 1 or more episodes of severe hypoglycemia and\u002For has hypoglycemia unawareness within the 6 months prior to screening\n* At least 2 confirmed fasting blood glucose values \\>270 mg\u002FdL (15.0 mmol\u002FL) (on 2 non-consecutive days) during screening\n* Self-reported change in body weight \\>5 kg within 3 months prior to screening\n* Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)\n* Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.\n* Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)\n* Poorly controlled hypertension at screening\n* Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)\u002Ftransient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure\n* Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1\u002FGIP receptor dual agonist, GLP-1\u002FGIP\u002FGluc receptor triple agonist) within 6 months prior to randomization",{"count":232,"type":21},1600,[234],"PHASE3","The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).",[237,28],"Obesity or Overweight","2026-06-19",{"date":216,"type":33},{"date":241,"type":33},"2026-03-23",{"date":243,"type":21},"2028-08-07",{"name":39,"class":40},122,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100644392","phase-3-a-study-to-find-out-if-the-study-drug-elecoglipron-helps-adults-with-type-2-diabetes-mellitus-by-comparing-it-with-semaglutide-a-medicine-already-used-to-treat-type-2-diabetes-mellitus-100644392","NCT07662213","A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus","A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)","Eluminate-2","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (NYHA IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":255,"type":21},1200,[234],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).",[28],"2026-06-18",{"date":216,"type":33},{"date":262,"type":21},"2026-07-06",{"date":264,"type":21},"2028-05-23",{"name":266,"class":40},"AstraZeneca",158,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":285,"locationsCount":286},"100644450","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-the-combination-of-elecoglipron-and-dapagliflozin-in-adults-with-type-2-diabetes-mellitus-100644450","NCT07662109","A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)","Eluminate-5","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":277,"type":21},2000,[234],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.",[28],{"date":216,"type":33},{"date":262,"type":21},{"date":284,"type":21},"2028-07-05",{"name":266,"class":40},178,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100644444","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-and-impaired-renal-function-on-background-dapagliflozin-100644444","NCT07662135","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)","Eluminate-4","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening\n* On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)\n* HbA1c value:\n\n  1. On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n  2. SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol\u002Fmol)\n* Impaired renal function\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":296,"type":21},900,[234],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).",[28,300],"Type 2 Diabetes With Chronic Kidney Disease",{"date":216,"type":33},{"date":262,"type":21},{"date":304,"type":21},"2028-07-13",{"name":266,"class":40},162,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100644348","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-alone-or-in-combination-with-dapagliflozin-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-100644348","NCT07662044","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)","Eluminate-1","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening\n* T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication\n* HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":316,"type":21},800,[234],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.",[28],{"date":216,"type":33},{"date":262,"type":21},{"date":323,"type":21},"2028-07-14",{"name":266,"class":40},138,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":343,"locationsCount":344},"100644119","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-on-background-insulin-100644119","NCT07664553","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)","Eluminate-3","Inclusion Criteria:\n\n* Diagnosed with T2DM for at least 90 days prior to screening\n* Stable treatment with background insulin and other background glucose-lowering medication(s)\n* HbA1c value of ≥ 7% to ≤ 10.5%\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis.\n* Severe congestive heart failure (NYHA IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2",{"count":335,"type":21},600,[234],"The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)",[28],{"date":340,"type":33},"2026-06-24",{"date":262,"type":21},{"date":264,"type":21},{"name":266,"class":40},120,{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":364},"100537467","an-observational-study-called-finerod-to-learn-more-about-the-use-of-the-treatment-finerenone-including-how-safe-it-is-and-how-well-it-works-under-real-world-conditions-100537467","NCT06278207","An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","Finerenone Research of Outcomes and Drug Utilization","FINEROD","Inclusion Criteria:\n\n* A minimum of 12 months of continuous enrolment in the databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR or claims system, depending on the database used\n* No recorded prescription for finerenone in the 12 months prior to the index date\n* Age of 18 years or older as of the index date\n* Evidence of T2D at any point before (and including) the index date.\n* CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date:\n\n  * A diagnosis code indicating CKD stage 2, 3, 4 or stage unspecified\n  * two UACR tests results ≥ 30 mg\u002Fg separated by at least 90 days and by not more than 540 days\n  * two different eGFR test results ≥ 15 mL\u002Fmin\u002F1.73 m2 AND \\\u003C 60 mL\u002Fmin\u002F1.73 m2 separated by at least 90 days and by not more than 540 days\n\nExclusion Criteria:\n\n\\- Kidney failure defined as follows:\n\n* Two different eGFR test results \\\u003C 15 mL\u002Fmin\u002F1.73 m2 separated by at least 90 days and by not more than 540 days;\n* Dependence on dialysis (at least 3 sessions over at least 90 days during the baseline period);\n* A diagnosis code indicating kidney failure or CKD stage 5; Kidney transplant",{"count":354,"type":21},50000,"This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems.\n\nThe researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone.\n\nThe data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests in this study.",[156,28],"2026-06-17",{"date":259,"type":33},{"date":360,"type":33},"2024-05-15",{"date":362,"type":21},"2026-09-30",{"name":167,"class":40},4,{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":383,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":393},"100536635","safety-and-effectiveness-of-endoscopic-intestinal-re-cellularization-therapy-in-individuals-with-type-ii-diabetes-100536635","NCT06267391","Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes","A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)","ReCET","Inclusion Criteria:\n\n* 22- 70 years of age, inclusive.\n* T2D diagnosis for at least 6 months.\n* HbA1C of 7.5-10.5%, inclusive, determined by the central laboratory.\n* BMI 27-40 kg\u002Fm2, inclusive.\n* On 2-4 non-insulin glucose lowering mediations or on monotherapy with either GLP-1 or GLP-1\u002FGIP medications, with no changes in medication or dosing for at least 12 weeks prior to the baseline visit.\n* Individualized metabolic surgery (IMS) score ≤ 95.\n* Weight stability (≤5% weight change) for at least 12 weeks prior to the screening visit.\n* Agree not to donate blood during participation in the study.\n* Able to comply with study requirements and understand and sign the Informed Consent Form.\n* Women of childbearing potential must be not pregnant and using an acceptable method of contraception throughout the study.\n* Willing and able to comply with study visits and study tasks as required per protocol.\n\nExclusion Criteria:\n\n* Diagnosed with type 1 diabetes.\n* History of diabetic ketoacidosis or hyperosmolar nonketotic coma.\n* Fasting serum C-peptide \\\u003C1 ng\u002FmL (333pmol\u002Fl).\n* Current use of insulin, or previous use of any types of insulin for \\>1 month at any time (except for treatment of gestational diabetes) in last 2 years.\n* Hypoglycemic unawareness.\n* History of ≥1 severe hypoglycemia episode in past 6 months\n* Discontinuation of a GLP-1RA or a GLP-1\u002FGIP dual-agonist within 6 months of the screening visit following at least one month of treatment.\n* Known autoimmune disease, including but not limited to, celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder, or as evidenced by a positive anti-glutamic acid decarboxylase (GAD) test.\n* Previous GI surgery that has changed GI anatomy or could limit treatment of the duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar procedures or conditions.\n* Known history of a structural or functional disorder of the upper GI tract that may impede passage of the device through the upper GI tract or increase risk of tissue damage during an endoscopic procedure, including eosinophilic esophagitis, stricture\u002Fstenosis, varices, diverticula, or other disorder of the esophagus, stomach and duodenum.\n* History of gastroparesis.\n* Acute gastrointestinal illness in the last 7 days.\n* Known history of irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease and Celiac disease.\n* History of chronic or acute pancreatitis.\n* Active hepatitis or active liver disease, or alanine aminotransferase (ALT) level \\>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory at screening visit. Patients with NAFLD are eligible if their ALT level is ≤3.0 times the ULN.\n* Current use of vitamin K antagonists, such as warfarin, or current use of direct-action oral anticoagulants (DOCAs) that cannot be safely discontinued periprocedurally.\n* Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 7 days before the procedure.\n* Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) from treatment through 4 weeks following the procedure. Alternative use of acetaminophen and low dose aspirin is allowed.\n* Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the screening visit.\n* Use of medications known to affect GI motility (e.g. metoclopramide\u002F Reglan)\n* Current use of weight loss medications such as Saxenda \\[liraglutide \\], Xenical® \\[orlistat\\], Acutrim® \\[phenylpropanolamine\\], Sanorex® \\[mazindol\\], Adipex® \\[phentermine\\], BELVIQ® \\[lorcaserin\\], Qsymia® \\[phentermine\u002Ftopiramate combination\\], Contrave® \\[naltrexone\u002Fbupropion\\], or other weight loss medications including over-the-counter \\[OTC\\] medications \\[for example, Allī®\\]) or have discontinued weight loss medications within 6 months.\n* Participation in any structured weight loss program or endoscopic weight loss intervention within 6 months of the screen visit.\n* Persistent anemia, defined as hemoglobin \\\u003C10 g\u002FdL.\n* Known history of hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c.\n* History of blood donation or transfusion within 3 months prior to the Screening Visit.\n* Unstable or paroxysmal cardiac arrhythmia.\n* Any of the following cardiovascular conditions within 6-months prior to screening visit: acute myocardial infarction, cerebrovascular accident (stroke), hospitalization due to congestive heart failure.\n* History of valvular heart disease or chronic heart failure (NYHA III or IV).\n* Estimated glomerular filtration rate (eGFR) ≤ 45 ml\u002Fmin\u002F1.73m2 calculated by CKD-EPI Creatinine Equation as determined by the central laboratory.\n* Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, who have clinically significant leukopenia, who are positive for the human immunodeficiency virus (HIV) or whose immune status makes the participant a poor candidate for clinical trial participation in the opinion of the investigator.\n* History of secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value outside the normal range at screening).\n* Presence of any implanted electronic devices that cannot be turned off during the procedure\n* Presence of duodenal or biliary stents.\n* Not a candidate for upper GI endoscopy or general anesthesia.\n* Active illicit substance abuse or alcoholism (\\>2 drinks\u002Fday regularly).\n* Active malignancy within the last 5 years (excluding non-melanoma skin cancers).\n* Women who are breastfeeding.\n* Participating in another ongoing clinical trial of an investigational drug or device.\n* Binge eating disorder, or any other mental or physical condition which, in the opinion of the study investigator, makes the participant a poor candidate for clinical trial participation.\n* Critically ill or has a life expectancy \\\u003C5 years.\n* Are investigator site personnel directly affiliated with this study and\u002For their immediate family member. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.","22 Years","70 Years",{"count":376,"type":21},264,[24],"This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.",[28,380,381,382,109],"Type2diabetes","Diabetes Mellitus, Type 2","Diabetes",[382,109,384],"Duodenal Mucosal Resurfacing",{"date":386,"type":33},"2026-06-22",{"date":388,"type":33},"2024-05-01",{"date":390,"type":21},"2026-10-01",{"name":392,"class":40},"Endogenex, Inc.",45,{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":402,"maxAge":71,"enrollmentInfo":403,"targetDuration":405,"studyType":153,"phases":4,"briefSummary":406,"conditions":407,"keywords":413,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":168},"100641243","automated-passive-case-finding-for-advanced-liver-fibrosis-in-masld-the-liverseek-programme-100641243","NCT07658755","Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme","Towards Universal Screening for Metabolic Dysfunction-Associated Liver Fibrosis in Primary Care: Evaluation of a Single-Step, Laboratory Informatión System-Driven Automated Case-Finding Strategy (LiverSeek)","LiverSeek","Inclusion Criteria:\n\n1. Age between 50 and 75 years (inclusive)\n2. Routine blood test processed in the Clinical Biochemistry Laboratory of Hospital General Universitario Gregorio Marañón, ordered by a primary care physician in one of the 11 affiliated SERMAS primary care centres\n3. Presence of at least one of the following metabolic risk factor combinations:\n\n   * ALT above the upper limit of normal AND HbA1c ≥6.5%\n   * ALT above the upper limit of normal AND BMI \\>30 kg\u002Fm²\n   * BMI \\>30 kg\u002Fm² AND HbA1c ≥6.5%\n\nExclusion Criteria:\n\n1. Age \\\u003C50 years or \\>75 years\n2. Known pre-existing liver disease (significant or advanced fibrosis, cirrhosis, hepatocellular carcinoma, prior liver transplantation)\n3. Prior fibrosis assessment within the preceding 12 months.","50 Years",{"count":404,"type":21},3000,"24 Months","LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care. The programme operates through the Laboratory Information System (LIS; Modulab\u002FBiwer Analytics) of the Clinical Biochemistry Laboratory at Hospital General Universitario Gregorio Marañón (HGUGM), covering approximately 350,000 inhabitants across 11 peri-urban primary care centres affiliated to SERMAS (Servicio Madrileño de Salud) in Madrid, Spain.\n\nWhen a high-risk patient (age 50-75 years with ≥1 of: ALT above ULN + HbA1c ≥6.5%; ALT above ULN + BMI \\>30; BMI \\>30 + HbA1c ≥6.5%) undergoes a routine blood test in primary care, the LIS automatically calculates FIB-4. If FIB-4 \\>1.30, the system reflexively orders ELF and MASEF from the same serum sample, without any action required from the primary care clinician. Patients with a positive second-step NIT (ELF ≥9.8 or MASEF ≥0.33) receive an automatic alert directing them to the Hepatology Advanced Practice Nurse for VCTE (FibroScan) and clinical evaluation.\n\nThe primary objective is to evaluate the prevalence of hepatic fibrosis in the high-risk population using this single-step automated strategy. Secondary objectives include head-to-head diagnostic comparison of FIB-4+ELF vs FIB-4+MASEF vs FIB-4+FAST for histologically-confirmed endpoints (significant fibrosis ≥F2, advanced fibrosis ≥F3, at-risk MASH), evaluation of the Liver Risk Score, and a health-economic analysis. A sub-study evaluates a nurse-led structured lifestyle intervention in NIT-positive patients.",[408,409,410,28,411,412],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Fibrosis","Non-alcoholic Fatty Liver Disease NAFLD","Obesity","Obesity Type 2 Diabetes Mellitus",[414,415,416,417,418,419,420,421,422,423,424],"MASLD","MAFLD","NAFLD","liver fibrosis","FIB-4","ELF","MASEF","screening","passive screening","advanced practice nurse","lifestyle intervention","2026-06-14",{"date":386,"type":33},{"date":428,"type":33},"2024-10-01",{"date":430,"type":21},"2027-09-01",{"name":432,"class":193},"Hospital General Universitario Gregorio Marañon",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":168},"100610819","an-observational-study-called-fine-real-korea-to-learn-more-about-the-use-of-the-drug-finerenone-in-people-with-chronic-kidney-disease-and-type-2-diabetes-in-a-routine-medical-care-setting-in-south-korea-100610819","NCT07232537","An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea","FINE-REAL Korea: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting in Korea","Inclusion Criteria:\n\n* Adult female or male participant - All genders (≥18 years old)\n* Diagnosis of CKD associated with T2D based on assessment by physician\n* Treatment according to local marketing authorization, finerenone 20 or 10 mg. Treatment should have been started up to 8 weeks before or after the ICF is signed.\n* Decision to initiate treatment with finerenone must be made before ICF is signed\n\nExclusion Criteria:\n\n* Participation in an investigational trial at any time during the course of this study\n* Contra-indications according to the local label",{"count":152,"type":21},"This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone are collected and studied.\n\nChronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and extra water from the blood. Type 2 diabetes occurs when the body does not produce enough insulin or does not use it effectively, leading to high blood sugar levels that can harm the kidneys. As a result, CKD can develop as a complication of T2D.\n\nThe study drug, finerenone, is already approved for doctors to prescribe to patients with CKD and T2D.\n\nFinerenone is a medication that works by blocking certain proteins known as mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse.\n\nThe main purpose of this study is to learn more about characteristics and treatment patterns of people with CKD and T2D who have recently started or will start finerenone treatment as prescribed by their doctor as part of their routine medical care in South Korea.\n\nThe FINE-REAL Korea study is designed to collect additional data on people with CKD and T2D who are treated with finerenone according to the approved product information, and it will work alongside the original FINE-REAL study (NCT05348733) to gather enough information for safety assessments in Korean population.\n\nTo achieve this, researchers will collect data on:\n\n* Clinical characteristics of participants, including their medical history related to CKD and T2D, blood pressure, and heart health.\n* Reasons for starting finerenone.\n* Reasons for stopping finerenone early.\n* The planned and actual duration of finerenone treatment.\n* The dosing of finerenone.\n* Other medications taken alongside finerenone.\n\nThe study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.\n\nOne specific concern is hyperkalemia, which refers to high potassium levels in the blood. This condition can occur when finerenone is used with certain blood pressure medications. Researchers want to understand how often hyperkalemia happens and whether it leads to:\n\n* Early discontinuation of finerenone treatment.\n* The need for dialysis, a procedure that filters waste from the blood.\n* Hospitalization for care.\n\nData for this study will be collected from medical records and through interviews conducted by study doctors during routine medical visits.\n\nParticipants will be involved in the study for up to 12 months, although this duration may be shorter if their finerenone treatment is stopped early.",[156,28],"2026-06-12",{"date":445,"type":33},"2026-06-15",{"date":447,"type":33},"2025-11-20",{"date":449,"type":21},"2028-01-28",{"name":167,"class":40},{"id":452,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":25,"conditions":455,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":459,"locationsCount":41},"100570240",{"count":20,"type":21},[24],[27,28],{"date":445,"type":33},{"date":35,"type":33},{"date":37,"type":21},{"name":39,"class":40},{"id":461,"slug":4,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":53,"conditions":464,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":469,"leadSponsor":470,"locationsCount":63},"100610479",{"count":51,"type":21},[24],[27,28],"2026-06-04",{"date":467,"type":33},"2026-06-08",{"date":58,"type":33},{"date":60,"type":21},{"name":62,"class":40},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":479,"maxAge":374,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":492,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":168},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years",{"count":481,"type":21},216,[24],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[109,485,486,487,488,489,490,28,491],"Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes (T2DM)",[493,494,495,496,497,498,499,500,501,502,503,504],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","2026-05-15",{"date":507,"type":33},"2026-05-19",{"date":509,"type":33},"2025-10-14",{"date":511,"type":21},"2027-02-16",{"name":513,"class":193},"University of Pennsylvania",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":71,"enrollmentInfo":522,"targetDuration":4,"studyType":22,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100600591","ultrasound-enhanced-propolis-therapy-for-healing-diabetic-foot-wounds-100600591","NCT07099482","\"Ultrasound-Enhanced Propolis Therapy for Healing Diabetic Foot Wounds\"","Effectiveness of Propolis Phonophoresis on Wound Healing in Diabetic Ulcer: a Randomized Controlled Trial","PEARL","Inclusion Criteria:\n\nAdults aged 18 to 75 years\n\nDiagnosed with type 1 or type 2 diabetes mellitus\n\nPresence of a diabetic foot ulcer classified as Grade 1 or 2 (Wagner classification)\n\nUlcer size between 1 cm² and 5 cm²\n\nAble and willing to provide informed consent\n\nExclusion Criteria:\n\nSevere infection or presence of osteomyelitis at the ulcer site\n\nUse of systemic immunosuppressants or corticosteroids\n\nKnown allergy or hypersensitivity to propolis\n\nPregnant or breastfeeding women\n\nParticipation in another clinical trial within the past 30 days",{"count":523,"type":21},80,[24],"This study aims to evaluate whether using ultrasound (phonophoresis) can help deliver propolis-a natural compound made by bees-more effectively into the skin to speed up wound healing in people with diabetic foot ulcers. Diabetic foot ulcers are a common and serious complication of diabetes and often take a long time to heal. Propolis has natural anti-inflammatory and antimicrobial properties that may promote healing, but it does not easily penetrate the skin. By using ultrasound to enhance absorption, this study tests whether combining propolis with phonophoresis is more effective than standard wound care alone. Participants will be randomly assigned to receive either the propolis ultrasound therapy or standard care. The study will measure wound size, healing time, pain, infection rates, and quality of life.",[527,27,28,528,529],"Diabetic Foot Ulcer t","Wound Management","Chronic Wound Healing","2026-05-05",{"date":532,"type":33},"2026-05-06",{"date":534,"type":21},"2026-05-30",{"date":536,"type":21},"2026-09-25",{"name":538,"class":193},"Sinai University",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":168},"100510955","a-study-of-glycemic-control-in-left-ventricular-assist-100510955","NCT05933161","A Study of Glycemic Control in Left Ventricular Assist","GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)","GLYCEM1C-LVAD","Inclusion Criteria:\n\n* Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010\n* Diagnosis of type II diabetes mellitus\n* Any antihyperglycemic regimen\n* Greater than 3 months out from LVAD implantation\n* Capable of utilizing smartphone device for LibreLink app for uploading glycemic data\n* Patients may be enrolled who have preexisting CGM in place.\n\nExclusion Criteria:\n\n* Type I diabetics\n* Unable to return at 3 month evaluation\n* Unwillingness to participate",{"count":179,"type":21},"The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.",[28,550,551],"Hyperglycemia","Hypoglycemia",[553],"Left Ventricular Assist Device (LVAD)",{"date":555,"type":33},"2026-05-08",{"date":557,"type":33},"2023-11-10",{"date":559,"type":21},"2027-07",{"name":561,"class":193},"Mayo Clinic",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":168},"100626250","polus-description-of-the-effectiveness-and-tolerability-of-luseogliflozin-in-patients-with-type-2-diabetes-100626250","NCT07433192","POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.","Multicenter Observational Study POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes in Real-world Clinical Practice.","POLUS","Inclusion Criteria:\n\n* Men and women aged 18 years and older.\n* Patients with type 2 diabetes.\n* Written informed consent of the patient to participate in the study.\n* No conditions that require emergency medical aid.\n* Treatment with luseogliflozin started 7 to 30 days prior to the inclusion visit as part of routine clinical practice and in accordance with the SmPC approved in the Russian Federation.\n* Presence of data on the parameters of interest (HbA1c, eGFR, BP, body weight), dated no later than 15 days from the date the treatment with luseogliflozin was started\n\nExclusion Criteria:\n\n* Patients cannot be included in this study if they meet at least one of the following exclusion criteria:\n* Known hypersensitivity to luseogliflozin or other components of Lusefi®.\n* Type 1 diabetes.\n* Decompensated type 2 diabetes.\n* Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.\n* Severe renal failure (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2), end-stage chronic kidney disease (CKD) or dialysis, as the treatment is predicted to be ineffective in this population of patients.\n* Diabetic ketoacidosis, diabetic coma or precoma.\n* Severe infections, pre- and postoperative period, or severe injury.\n* Any suspected or confirmed malignant neoplasm, including a history of malignancy within ≤5 years prior to screening, excluding successfully treated basal cell carcinoma and squamous cell carcinoma of the skin or in situ cervical cancer.\n* Urinary tract infection (confirmed or suspected).\n* Other concomitant disorders considered by the investigator to affect the natural progression of the disease and significantly impact the treatment results.\n* Predictable unwillingness of the patient to adhere to the treatment regimen and\u002For cooperate with the investigator.\n* Participation of the patient in another clinical study within 3 months (6 months for biological medicinal products) prior to the inclusion visit or during this study.",{"count":571,"type":21},300,"In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.",[28],"2026-04-29",{"date":138,"type":33},{"date":577,"type":33},"2026-03-02",{"date":430,"type":21},{"name":580,"class":40},"Servier Russia",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":589,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":168},"100636062","effect-of-beetroot-juice-on-cardiovascular-and-autonomic-responses-to-exercise-in-adults-with-type-2-diabetes-100636062","NCT07560800","Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes","Effect of Beetroot Juice on Cardiovascular and Autonomic Responses During and After Exercise in Adults With Type 2 Diabetes","DiaBEET","Inclusion Criteria:\n\n* Clinically diagnosed Type 2 Diabetes Mellitus\n* Aged 40 to 65 years\n* Not treated with insulin\n* Stable diabetes medication regimen for at least 3 months\n* Able to understand the study information and provide informed consent\n* Able to safely perform light-to-moderate cycling exercise\n\nExclusion Criteria:\n\n* Current or recent use of insulin\n* Use of organic nitrates (e.g., glyceryl trinitrate) or phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil)\n* Use of systemic antibiotics within the specified preparation period or regular use of antiseptic\u002Fantibacterial mouthwash during study participation\n* Use of supplements known to interfere with nitric oxide metabolism within the defined preparation period\n* Unstable or clinically significant cardiovascular disease\n* Uncontrolled hypertension or any condition that makes exercise unsafe\n* Chronic kidney disease, history of kidney stones, or other relevant renal conditions\n* Neurological, musculoskeletal or systemic disorders that impair safe participation\n* Known or suspected allergy or intolerance to beetroot, lemon or any component of the study products\n* Pregnancy or breastfeeding\n* Inability to comply with study preparation requirements","40 Years","65 Years",{"count":179,"type":21},[24],"This study will investigate whether a single dose of beetroot juice can improve cardiovascular responses and recovery after exercise in adults with Type 2 Diabetes.\n\nType 2 Diabetes is associated with higher blood pressure, impaired blood vessel function, and reduced autonomic control of the heart, all of which increase cardiovascular risk and may affect how the body responds to and recovers from physical activity. Beetroot juice is naturally rich in dietary nitrate, which is converted in the body into nitric oxide, a molecule that helps blood vessels relax and improve blood flow. While these effects have been demonstrated in healthy individuals, less is known about their impact in people with Type 2 Diabetes.\n\nIn this study, approximately 16 to 20 adults aged 40 to 65 years with Type 2 Diabetes will take part. After an online screening and consent process, eligible participants will attend two laboratory visits at Oxford Brookes University. In a randomised, double-blind, placebo-controlled crossover design, participants will receive beetroot juice during one visit and a nitrate-depleted placebo during the other visit.\n\nDuring each visit, participants will undergo physiological measurements, including blood pressure, heart rate, oxygen saturation, and capillary blood glucose. Participants will then complete a short session of supervised, light-to-moderate cycling exercise. Measurements will continue during the recovery period to assess how quickly the cardiovascular system returns to resting levels.\n\nThe main outcomes are systolic blood pressure and heart rate variability during recovery, which reflect cardiovascular regulation and autonomic function. Secondary outcomes include diastolic blood pressure, heart rate, blood glucose, and markers related to nitric oxide availability.\n\nThis study may help determine whether a simple, dietary-based intervention such as beetroot juice can support cardiovascular function and improve recovery after exercise in people living with Type 2 Diabetes.",[28,183,595],"Autonomic Nervous System Diseases",[597,598,599,600,601,602,603,604,605,606],"Beetroot juice","Dietary nitrate","Nitric oxide","Heart rate variability","Autonomic function","Blood pressure","Exercise recovery","Submaximal exercise","Endothelial function","Crossover trial","2026-04-28",{"date":609,"type":33},"2026-05-01",{"date":611,"type":21},"2026-04-02",{"date":613,"type":21},"2026-07-31",{"name":615,"class":193},"Oxford Brookes University"]